Ask OQRO is part of OQRO Pro. Everything else on OQRO is free.
Cookies
Only to see which pages are hard to use, so we can fix them. Nothing is used for ads, and what you type stays hidden (Microsoft Clarity, PostHog). Privacy Policy
Mira Pharmaceuticals (MIRA) · oqro.io/stocks/MIRA · printed today. Every figure comes from a public filing, linked on the page online. Not investment advice.
Questions about Mira Pharmaceuticals insider trading
Have Mira Pharmaceuticals insiders bought shares recently?
No open-market purchase by an insider of Mira Pharmaceuticals was filed in the last 90 days. The latest on record was on May 21, 2024.
How often do Mira Pharmaceuticals insiders buy and sell shares?
Since 2023, Mira Pharmaceuticals insiders reported 10 open-market purchases and 23 sales on Forms 4 and 5, with purchases in 2 different years, most recently 2024.
Who is selling Mira Pharmaceuticals stock?
No open-market sale by an insider of Mira Pharmaceuticals (MIRA) was filed with the SEC in the last 90 days.
Do members of Congress trade MIRA?
No trade in Mira Pharmaceuticals (MIRA) was disclosed by a member of Congress in the last 12 months.
Where does this data come from?
From official filings only: SEC Forms 4, 5 and 144 for insiders, House and Senate periodic transaction reports for Congress, SEC Form 13F for funds, Form 8-K for company events and USAspending for federal contracts. Every record on OQRO links to its source. It is public data, not investment advice.
−73.7% (−$1.03) from Nov 19, 2025 to Nov 19, 2026 · adjusted daily closes
No disclosed open-market insider trades, politician trades or fund 13F changes in this period.
Adjusted close went from $1.40 on Nov 19, 2025 to $0.3683 on Nov 19, 2026 (−73.7%). Disclosed in this range: 0 insider trades, 0 pre-arranged insider sales, 0 Congress trades.
$0.00$1.00$1.50$2.00$0.3683
DecJan 2026FebMarAprMayJunJulAugSepOctNov
Insider and Congress marks sit on the trade date stated in the filing; solid is a purchase, hollow a sale. A number means several trades too close to tell apart at this range: pick a shorter range or open it for the list. Congress amounts are official ranges; mark size uses the lower bound. Past moves are not a forecast.
Counts of filings OQRO holds, by the date each was filed or the award started. Every figure links to its official SEC, House, Senate or USAspending record.
Pharmaceutical Preparations company based in Miami, Fl.
Last 12 months
−73.7%
S&P 500 +8.0% over the same dates
Market value
$15.5M
Close of Nov 19, 2026 × shares outstanding (per ADS where it applies)
S&P 500 +8.0% over the same dates. Prices adjusted for splits and dividends.
Short interest: 282K shares sold short (0.7% of shares outstanding), −19.3% vs the previous count, 1.4 days of normal trading to buy them back. FINRA, as of Oct 30, 2026. Short interest history
Prices are daily closes from Polygon.io. Company figures come from its own SEC filings. Past moves are not a forecast. OQRO reports what was filed and never tells you what to buy or sell.
Since Nov 18, 2025, MIRA is down 73.9% and the index fund is up 8.5%: 82 points behind the market. Traders call a stock that beats the index over a period a relative-strength leader.
How much MIRA moves
A usual day
±2.1%Half of the sessions moved less than this, half moved more.
Daily range (ATR 14)
19.1%How far the price usually travels in a session, the gap from the day before included. Wilder's 14-session average.
Largest one-day fall
−37.7%Nov 19, 2026
Largest one-day rise
+22.3%Mar 23, 2026
Deepest fall of the year
−77.4%From the close of Dec 19, 2025 to Nov 19, 2026.
Days of 5% or more
50Out of 252 sessions, in either direction.
Beta 1.5(1 year vs SPY)
End-of-day prices. These figures describe the past year and say nothing about what comes next. Beta: how much the stock moved, on average, for each 1% move of the S&P 500 fund over 250 trading days (1 = in step with it).
Owners above 5%
No Schedule 13D or 13G filing on MIRA over the last three years: no investor has reported crossing 5% of its stock in that time.
Source: SEC Schedules 13D and 13G, which anyone owning more than 5% of a class of stock must file. A 13D filer may seek to influence the company; a 13G filer is passive. Filings before December 2024 are free text and read from their cover page: a percent or share count that is not stated plainly is left blank. Each line links to the filing.
Insider buying and selling since 2023
Insiders of Mira Pharmaceuticals reported 10 open-market purchases and 23 sales since 2023; purchases in 2 different years, most recently 2024.
Year
Bought
Sold
2024
$8.2K8×8 trades
$526K3×3 trades
2023
$1.93M2×2 trades
$704K20×20 trades
Open-market purchases (code P) and sales (code S) on Forms 4 and 5. Up to Sep 2024 from the SEC's Insider Transactions Data Sets; since Oct 2024 from each filing as it is published. A trade filed twice (an amendment) counts once. Dollar totals use the price the filer reported; lines with no price count as trades without a value.
Red flags in its filings
Jul 31
Notice of delisting or failure to meet listing rules
From the company's 8-K, 10-K and 10-Q filings over the last two years. A flag is a reason to read the filing, not a verdict: many departures are planned retirements and many listing notices are resolved. Insider sales are shown for timing only; they are separate filings.
OQRO Intelligence
Written by OQRO's software from the last 12 months on record · Nov 19, 2026
Insiders. In the 12 months to Nov 19, 2026, insiders of Mira Pharmaceuticals filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions. In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 2 open-market sales (about $134K, in 1 filing). (Mira Pharmaceuticals on OQRO)
Contracts, lobbying and filings. FINRA short interest for MIRA on the settlement date of Oct 30, 2026 was 282,319 shares (-19.27% on the previous report), about 1.44 days of average volume.
Company reports, price and press. Mira Pharmaceuticals filed a Form 8-K on Jul 31, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange. The company's own opening sentence of that report reads: "On July 27, 2026, Mira Pharmaceuticals, Inc. (the 'Company') received a letter (the 'Letter') from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ('Nasdaq') indicating that, based upon the closing bid price of th..."
Who holds it. 26 funds reported a stake in Mira Pharmaceuticals in their 13F for Q2 2026. The largest by value: VANGUARD CAPITAL MANAGEMENT LLC (32.5% of the value reported), Cross Staff Investments Inc (15.5% of the value reported), GEODE CAPITAL MANAGEMENT, LLC (13.1% of the value reported).
Things to keep in mind. These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why. A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade. An 8-K item says what the company reported, not what it means for the share price.
Facts used for this text
Every number, name, date and link in the text above comes from this list; software checks that before the text is stored. This text was assembled directly from the facts, without a language model.
Insiders
In the 12 months to Nov 19, 2026, insiders of Mira Pharmaceuticals filed 0 open-market purchases (about $0, in 0 filings, by 0 people) and 0 open-market sales (about $0, in 0 filings, by 0 people). One Form 4 can list many transactions.
In the 12 months before that, they filed 0 open-market purchases (about $0, in 0 filings) and 2 open-market sales (about $134K, in 1 filing).
Contracts, lobbying and filings
FINRA short interest for MIRA on the settlement date of Oct 30, 2026 was 282,319 shares (-19.27% on the previous report), about 1.44 days of average volume.
Company reports, price and press
Mira Pharmaceuticals filed a Form 8-K on Jul 31, 2026 (Item 3.01) that OQRO classes as: received a notice from its stock exchange.
The company's own opening sentence of that report reads: "On July 27, 2026, Mira Pharmaceuticals, Inc. (the 'Company') received a letter (the 'Letter') from the Listing Qualifications Staff of The Nasdaq Stock Market LLC ('Nasdaq') indicating that, based upon the closing bid price of th..."
Mira Pharmaceuticals filed a Form 8-K on Jun 8, 2026 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "Effective June 6, 2026, Alan Weichselbaum will be no longer serving as the Chief Financial Officer of Mira Pharmaceuticals, Inc. (the 'Company'). Mr. Weichselbaum’s departure was not the result of any disagreement with the Compan..."
Mira Pharmaceuticals filed a Form 8-K on Dec 22, 2025 (Item 5.02) that OQRO classes as: changed a top executive or board member.
The company's own opening sentence of that report reads: "On December 16, 2025, the Compensation Committee of the Board of Directors of MIRA Pharmaceuticals, Inc. (the 'Company') approved certain short-term and long-term incentive awards for the Company’s Chief Executive Officer, Erez A..."
MIRA closed at $0.591 on Nov 18, 2026, the last session on or before the end of the period.
From Oct 19, 2026 to Nov 18, 2026, the close moved from $0.6421 to $0.591, a change of −8.0%.
Who holds it
26 funds reported a stake in Mira Pharmaceuticals in their 13F for Q2 2026. The largest by value: VANGUARD CAPITAL MANAGEMENT LLC (32.5% of the value reported), Cross Staff Investments Inc (15.5% of the value reported), GEODE CAPITAL MANAGEMENT, LLC (13.1% of the value reported).
Things to keep in mind
These are counts of the filings OQRO holds, in the days they were filed; a busy or quiet month does not say why.
A Form 4 reports a transaction; it does not say why it was made, and some follow trading windows or pre-arranged plans. Congress reports give only amount ranges and arrive after the trade.
An 8-K item says what the company reported, not what it means for the share price.
Share price moves are listed as context only; the filing does not explain them and other news can move a price.
This describes public filings. It is not investment advice.
Every annual report has a section where the company's managers explain the year's results (Item 7, Management's discussion and analysis). In this report it runs to about 3,000 words.
From “Overview”, in the company's words
MIRA Pharmaceuticals, Inc. (Nasdaq: MIRA) is a clinical-stage pharmaceutical development company advancing two neuroscience programs targeting neurologic and neuropsychiatric disorders. The company holds exclusive rights in the U.S., Canada, and Mexico for Ketamir-2 and MIRA-55, two novel drug candidates designed to address unmet medical needs in pain management, depression, PTSD and cognitive function. Ketamir-2 is a next-generation oral NMDA-receptor antagonist currently being evaluated in an ongoing Phase 1 clinical trial in healthy volunteers. The single-ascending-dose (SAD) portion of the study has been completed, and data remain blinded pending full analysis.
What the section covers (16 headings)
FINANCIAL CONDITION AND RESULTS OF OPERATIONS
Overview
Components of our Results of Operations
Research and Development Expenses
General and Administrative Expenses
Other Income, net
Liquidity and Capital Resources
Cash Flows
Net Cash Used in Operating Activities
Net Cash Provided by Financing Activities
Recently Issued and Adopted Accounting Pronouncements
Off-Balance Sheet Arrangements
Summary of Critical Accounting Policies and Estimates
Investments in Equity Securities, at Fair Value
And 2 more headings in the filing.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. The quote is the opening of the managers' discussion, cut at a sentence; the word count is estimated from its length. Not investment advice.
Risk factors in the annual report
Latest annual report filed Mar 31, 2026, compared with the one filed Mar 28, 2025. Read the filing
New risk factors in the latest annual report (9 headings)
We depend on a limited number of suppliers for materials and components required to manufacture our product candidates.
SKNY does not own rights to SKNY-1 Conflicts of interest may arise between SKNY and MIRALOGX.
Our product candidates, if approved, may be unable to achieve the expected market acceptance and, consequently, limit our ability to generate revenue from new products.
SKNY does not own rights to SKNY-1.
SKNY’s rights to SKNY-1 are subject to royalties.
Conflicts of interest may arise between SKNY and MIRALOGX.
SKNY’s product candidates, if approved, may not achieve the expected market acceptance and, consequently, limit SKNY’s ability to generate revenue.
SKNY expects to face intense competition, often from companies with greater resources and experience than it has.
And 1 more heading in the filing.
No longer listed (14 headings from the year before)
We depend on rights to Ketamir-2 that are or will be licensed to us.
We have been granted a license to the right to develop Ketamir-2 in the United States in human and pet application, but we have not been granted a license to the rights to patents covering Ketamir-2 in foreign jurisdictions.
We will need to raise additional financing for the continuation of our operations.
Our operating results may fluctuate, which could have a negative impact on our ability to grow our client base, establish sustainable revenues and succeed overall.
Our future success will largely depend on the success of Ketamir-2 and MIRA-55 and any future product candidates, which development will require significant capital resources and years of clinical development effort.
We may not successfully integrate with SKNY following our potential upcoming acquisition Results of pre-clinical studies and earlier clinical trials are not necessarily predictive indicators of future results.
We will need to further increase the size and complexity of our organization in the future, and we may experience difficulties in managing our growth and executing our growth strategy.
Any failure by us to comply with existing regulations could harm our reputation and operating results.
And 6 more headings in the filing.
Legal proceedings (Item 3)
None reported.
Source: SEC EDGAR, Form 10-K filed Mar 31, 2026. Headings are the titles the company gives each risk; OQRO compares them with the year before by their words, so a heading that was reworded a lot shows up as both new and no longer listed. Companies list the risks they face, not forecasts.
Latest results: quarter ending Sep 30, 2026
Revenue
—
Free cash flow, last 12 months
—
Cash from operations minus capital spending
Net debt
—
Debt —, cash $2.5M, at Sep 30, 2026
Net income, last 12 months
−$9.76M
From the company's own quarterly and annual reports to the SEC. Free cash flow (cash from operations minus capital spending), net debt (debt minus cash) and 12-month totals are calculated by OQRO.
Off-exchange trading: 58.3% of the shares traded over the latest 4 published weeks changed hands away from the exchanges (3.3% on ATS, 55.0% with other brokers), below its 26-week average of 72.3%. Weeks of Sep 21 to Oct 16, 2026.
Week of Apr 20ATSOther off-exchangeFull height = all shares tradedWeek of Oct 12
Largest ATS: UBS ATS (17.0%), IBKR ATS (16.5%), ONECHRONOS (7.9%), as a share of this stock's ATS volume over the same 4 weeks.
An ATS, often called a dark pool, is a private trading venue run by a broker where orders are not shown publicly before they trade. Other off-exchange trades are mostly retail orders filled by wholesale brokers. A high share is common and says nothing by itself about where the price goes. FINRA OTC Transparency data, published 2 weeks after each week for the largest stocks and 4 weeks for others; total volume from our daily price data.